SCHEMBL25939837

SCHEMBL25939837

CC(C)(C)COCC=CCOC(=O)NC(C)(C)C

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ ALOX15 P16050 1/20 0.30
▸ TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23613239 1.00 ALOX15 (0.30) ALOX15TSHR
SCHEMBL25043435 0.82 ALOX15 (0.32) ALOX15TSHR
SCHEMBL22288335 0.80 TSHR (0.33) ALOX15TSHR
SCHEMBL28454873 0.80 TSHR (0.33) ALOX15TSHR
SCHEMBL22288373 0.79 TSHR (0.32) ALOX15TSHR
SCHEMBL23933244 0.79 TSHR (0.32) ALOX15TSHR
SCHEMBL28628187 0.79 TSHR (0.32) ALOX15TSHR
SCHEMBL7807640 0.77 KMT2A (0.42) ALOX15TSHR
SCHEMBL13141355 0.74 CYP2C19 (0.33) —
SCHEMBL25939779 0.74 CYP2C19 (0.33) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814391-B2 Macrocyclic compounds for the treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2023-11-14 — — US disclosed
US-11718626-B2 Macrocyclic compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2023-08-08 — — US disclosed
US-11718626-B2 Macrocyclic compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2023-08-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718626-B2 Macrocyclic compounds for treatment of medical disorders CFD, TFPI, CFH ALOX15 148/4885TSHR 2042/4885
US-11814391-B2 Macrocyclic compounds for the treatment of medical disorders CFD, TFPI, CFH ALOX15 443/4885TSHR 1357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback